PSMA-Targeting Dual-Target Radiopharmaceuticals for Prostate Cancer Imaging
NCT07934056, Early phase 1, Active not recruiting, The First Affiliated Hospital of Soochow University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | PSMA-Targeting Dual-Target Radiopharmaceuticals for Prostate Cancer Imaging | ClinicalTrials.gov |
| NCT number | NCT07934056 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Early phase 1 | ClinicalTrials.gov |
| Enrollment | 30 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The First Affiliated Hospital of Soochow University | ClinicalTrials.gov |
| Conditions | Prostate Cancer | ClinicalTrials.gov |
| Interventions | 68Ga-Labeled EphA2/PSMA Dual-Target Radiotracer PET/CT imaging, 68Ga-Labeled ACP3/PSMA Dual-Target Radiotracer PET/CT imaging | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Safety | From radiotracer injection to 24 hours post-injection | Participants who experience at least one new or worsening adverse event during the observation period will be counted. Each participant will be counted once, regardless of the number of events. | ClinicalTrials.gov |
| Primary | Diagnostic efficacy | Through study completion, an average of 6 months | At the patient level, the detection rate will be calculated as the percentage of participants with an evaluable \[68Ga\]Ga-Dual-Target Radiotracer PET/CT scan showing at least one PET-positive tumor lesion. The number of PET-positive tumor lesions per participant will also be recorded. At the lesion level, tracer uptake will be quantified using the maximum standardized uptake value (SUVmax), and lesion contrast will be assessed using the tumor-to-background ratio (TBR). | ClinicalTrials.gov |
| Secondary | Dosimetry | Through study completion, an average of 6 months | The absorbed dose from \[68Ga\]Ga-Dual-Target Radiotracer will be estimated separately for each target organ and expressed in milligrays per megabecquerel of administered activity (mGy/MBq). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)